We report the case of a patient with synchronous TNBC and HER2-amplified breast cancer successfully treated to pathologic complete response by time of mastectomy with a modified hybrid KN522 and TCHP neoadjuvant regimen. The gene discussed is ERBB2; the disease is breast carcinoma.